Sumitomo Pharma has received regulatory approval in Japan for a pioneering stem cell based treatment for Parkinson’s disease, marking a major step forward for regenerative medicine. The therapy, known as Amchepry, uses induced pluripotent stem cells that are transformed into dopamine producing nerve cells and transplanted into the patient’s brain.

Parkinson’s disease occurs when dopamine producing neurons deteriorate, leading to symptoms such as tremors, stiffness and impaired movement. The new therapy aims to replace these lost cells and restore dopamine production, potentially improving motor function in patients who no longer respond adequately to existing medicines.

The approval was granted under Japan’s conditional and time limited framework for regenerative therapies, designed to accelerate access to innovative treatments while further data is gathered. Sumitomo Pharma plans to conduct additional post marketing studies to confirm long term safety and effectiveness.

Developed in collaboration with regenerative medicine company RACTHERA and supported by research from Kyoto University, the therapy is widely seen as the first commercially approved Parkinson’s treatment derived from iPS cells. If successful in broader clinical use, it could open the door for similar cell based therapies targeting other neurological disorders.